RT Journal Article
SR Electronic
T1 Efficacy and safety of treating symptomatic, primary focal osteochondral lesions of the patella with a combination of intra-articular injection of hyaluronic acid (HAi) and radial extracorporeal shock wave therapy (rESWT) or HAi alone: a retrospective two-cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.29.20164111
DO 10.1101/2020.07.29.20164111
A1 Cao, Jin
A1 Huang, Heqin
A1 Zhang, Changgui
A1 Yang, Liu
A1 Schmitz, Christoph
A1 Duan, Xiaojun
YR 2020
UL http://medrxiv.org/content/early/2020/07/30/2020.07.29.20164111.abstract
AB Background This study tested the hypothesis that a combination of intra-articular injection of hyaluronic acid (HAi) and radial extracorporeal shock wave therapy (rESWT) is more effective than HAi alone in the treatment of symptomatic, primary focal osteochondral lesions of the patella (sPFOLP).Methods We performed a retrospective analysis of n=81 subjects with unilateral sPFOLP who were treated with respectively HAi+rESWT (n=36) or HAi alone (n=45) at the outpatient department of our hospital between January 1st, 2014 and January 31th, 2018. Subjects in both cohorts also received education with special attention to reduction of going up and down the stairs, squatting and specific activities, as well as non-opioid analgesics if necessary. Efficacy was assessed using the pain visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, which were examined at baseline (BL) and six weeks (W6), three months (M3) and six months (M6) after BL, as well as during a last follow-up examination (LE) which was performed at 37.6 ± 1.7 (mean ± standard error of the mean) months after BL (range, 12-59 months). In addition, measurements of the area of the patellar bone marrow edema (PBME) on sagittal, fat suppression sequence magnetic resonance imaging (MRI) scans of the knee were performed at BL, M3, M6 and LE.Results Subjects who were treated with HAi+rESWT showed significantly smaller mean VAS pain scores at W6, M3 and M6, significantly smaller mean WOMAC scores at W6, M3 and LE and significantly smaller mean PBME areas at M3, M6 and LE than subjects who were treated with HAi alone. No severe adverse events were observed.Discussion The results of this study suggest that HAi+rESWT is safe and more effective than HAi alone in the treatment of sPFOLP. This result should be verified in adequate randomized controlled trials.Level of evidence Level III; retrospective two-cohort study.Competing Interest StatementThis study was performed with the radial extracorporeal shock wave device Swiss DolorClast, which is manufactured and distributed by Electro Medical Systems (Nyon, Switzerland). CS has received research funding at LMU Munich and consulted (until December 31st, 2017) for Electro Medical Systems. However, Electro Medical Systems had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All other authors declare no competing interests.Funding StatementThis study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for this retrospective study was granted by the Ethics Committee of the Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China (registration number KY201915). Because the study design did not require any additional interaction with the subjects there was no need to obtain consent for participation in this retrospective study according to the rules and regulations of Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing 400038, China.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and analyzed during this study are available from the corresponding author on reasonable request, taking into account any confidentiality.BLbaselineBMIbody mass indexEFDenergy flux densityEFD+positive energy flux densityESWTextracorporeal shock wave therapyFFisher’s exact testfESWsfocused extracorporeal shock wavesfESWTfocused extracorporeal shock wave therapyGLM-RMgeneral linear model repeated measuresHAhyaluronic acidHAiintra-articular injection of hyaluronic acidkgkilogramLElast follow-up examinationM3three months after baselinem2squared meterM6six months after baselinemaxmaximum valueminminimum valuemJ/mm2millijoule per squared millimetermlmilliliterMRImagnetic resonance imagingOAosteoarthritisPBMEpatellar bone marrow edemarESWsradial extracorporeal shock wavesrESWTradial extracorporeal shock wave therapyRCTrandomized controlled trialSDstandard deviationSEMstandard error of the meansPFOLPsymptomatic, primary focal osteochondral lesions of the patellaTunpaired t testVASvisual analog scaleW6six weeksWOMACWestern Ontario and McMaster Universities Osteoarthritis Index